Description

Description

Diajard Forte XR 12.5/2.5/1000mg is a prescription medicine manufactured by Highnoon Laboratories, bringing together three active ingredients, Empagliflozin, Linagliptin, and Metformin, in a single extended-release tablet. This triple fixed-dose combination is designed for adults with type 2 diabetes mellitus whose blood sugar control requires more than one or even two mechanisms of action working together. Empagliflozin belongs to the sodium-glucose co-transporter 2 (SGLT2) inhibitor class, working by reducing glucose reabsorption in the kidneys and promoting its removal through urine. In this strength, both Empagliflozin and Linagliptin are set at intermediate levels within the Diajard Forte XR range, while Metformin remains at its standard extended-release strength, making this combination typically suited for patients whose treatment plan calls for a more measured dose of the two non-Metformin components. Linagliptin belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, helping the body produce more insulin when blood sugar is elevated while reducing the amount of glucose released by the liver. Metformin, present here in extended-release form, belongs to the biguanide class and works mainly by decreasing glucose production in the liver while improving the body’s sensitivity to insulin. Each pack of Diajard Forte XR 12.5/2.5/1000mg contains 14 tablets, produced under the quality standards maintained by Highnoon Laboratories.

Ingredients

Diajard Forte XR 12.5/2.5/1000mg contains three active ingredients: Empagliflozin at a strength of 12.5 milligrams, Linagliptin at a strength of 2.5 milligrams, and Metformin Hydrochloride, in extended-release form, at a strength of 1000 milligrams per tablet. The formulation also includes inactive excipients such as extended-release matrix-forming agents, binding materials, and film-coating components, which work together to control the gradual release of Metformin and support the tablet’s overall structural integrity. These excipients do not carry therapeutic activity themselves but are essential to the tablet’s release mechanism and stability.

Dosage Form

Diajard Forte XR 12.5/2.5/1000mg is available as an oral extended-release film-coated tablet. Each pack contains 14 tablets, providing a supply suited to a once-daily triple combination treatment schedule as directed by a physician. Owing to its extended-release design, the tablet should be swallowed whole and must not be crushed, split, or chewed, as this could interfere with the controlled release mechanism.

Uses

Diajard Forte XR 12.5/2.5/1000mg is used to help improve blood sugar control in adults with type 2 diabetes mellitus, particularly where a physician determines that this intermediate combination of Empagliflozin and Linagliptin alongside extended-release Metformin is appropriate for the patient’s individual treatment needs. It is generally used alongside dietary changes and regular physical activity as part of a broader diabetes management plan. This medicine is not intended for individuals with type 1 diabetes or for the management of diabetic ketoacidosis. The suitability of this specific strength for any individual patient should always be confirmed through proper medical assessment.

How to Use

Diajard Forte XR 12.5/2.5/1000mg should be taken exactly as directed by a prescribing physician, typically once daily with the evening meal, which may help support tolerability and the intended extended-release action of the Metformin component. The tablet must be swallowed whole with a glass of water and should never be crushed, split, or chewed, as doing so could disrupt the extended-release formulation and alter how the medicine is absorbed. Patients should continue to follow any dietary and lifestyle recommendations provided by their doctor and must never modify the dosage without medical advice. Regular monitoring of blood sugar levels, kidney function, and overall hydration status is typically recommended throughout treatment, given the combined nature of this triple therapy.

Side Effects

Diajard Forte XR 12.5/2.5/1000mg may cause side effects in some individuals, although not everyone will experience them. Commonly reported effects include gastrointestinal symptoms such as mild nausea, diarrhea, or stomach discomfort linked to the Metformin component, along with urinary tract infections, genital yeast infections, and increased urination associated with the Empagliflozin component. Effects linked to Linagliptin, such as headache, upper respiratory symptoms, or joint discomfort, may also occur. Some patients may notice mild dizziness or symptoms related to dehydration. Rare but serious effects requiring immediate medical attention include signs of lactic acidosis, such as unusual muscle pain, difficulty breathing, or unexplained fatigue; signs of pancreatitis, such as persistent abdominal pain; or ketoacidosis with normal blood sugar readings, presenting as nausea, vomiting, or unusual tiredness. Patients with kidney or liver concerns, a history of pancreatitis, heavy alcohol use, dehydration, or recurrent urinary infections should discuss these factors with their doctor before starting this medicine, given the combined nature of this triple therapy.

Pregnancy & Breastfeeding

The use of Diajard Forte XR 12.5/2.5/1000mg during pregnancy or breastfeeding should only occur under the specific direction of a qualified healthcare provider, as its suitability depends on individual clinical circumstances. Women who are pregnant, planning pregnancy, or breastfeeding should discuss their situation with their doctor before starting or continuing this combination medicine.

Storage Instructions

Diajard Forte XR 12.5/2.5/1000mg tablets should be stored in a cool, dry place away from direct sunlight and excess humidity, at the room temperature indicated on the packaging. Tablets should remain in their original blister pack until they are ready to be used, helping protect them from moisture and light exposure. Keep out of reach of children and pets, and avoid storage in areas with fluctuating temperatures such as bathrooms or vehicles.

FAQS

Q: How does Diajard Forte XR 12.5/2.5/1000mg differ from other Forte XR strengths?
It uses intermediate doses of both Empagliflozin and Linagliptin alongside the standard Metformin strength, positioning it between the lower and higher combination options.

Q: Can Diajard Forte XR 12.5/2.5/1000mg tablets be split or crushed?
No, the tablet should always be swallowed whole, as splitting or crushing can interfere with its extended-release mechanism.

Q: Is this triple combination usually a starting treatment?
It is generally not a first-choice starting treatment and is more often prescribed after a patient’s response to fewer medicines or lower doses has been assessed by a doctor.

Q: What monitoring is typically recommended with this combination?
Doctors usually recommend periodic checks of kidney function, hydration status, and blood sugar response given the combined action of three active ingredients.

Disclaimer

Always use this medicine strictly according to your doctor’s instructions and prescribed dosage.